Sublingual immunotherapy: A comprehensive review - 17/08/11
Davie, Fla, Ciudad Juárez, Mexico, Copenhagen, Denmark, College Station, Tex, New York, NY, and Denver, Colo
Abstract |
Sublingual immunotherapy (SLIT) has been used with increasing frequency in Europe and is viewed with increasing interest by allergists in the United States. To address this interest, a Joint Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology’s Immunotherapy and Allergy Diagnostic Committees reviewed the available literature on SLIT and prepared this report. The task force concluded that despite clear evidence that SLIT is an effective treatment, many questions remained unanswered, including effective dose, treatment schedules, and overall duration of treatment. Until these have been determined, an assessment of the cost/benefit ratio of the treatment cannot be made. SLIT does appear to be associated with few serious side effects, but it has not been administered in high-risk asthmatic patients, nor in the studies reviewed has it been administered as a mixture of non–cross-reacting allergens. Furthermore, there is currently no allergy extract approved for this use in the United States, nor is there a Current Procedural Terminology code for billing purposes. All of these factors should be given careful consideration by anyone contemplating initiating SLIT treatment for their allergic patients.
Le texte complet de cet article est disponible en PDF.Key words : Sublingual-swallow immunotherapy, sublingual-spit immunotherapy, allergen immunotherapy, allergic asthma, allergic rhinitis
Abbreviations used : AAAAI, AE, CMD, CPT, DBPC, ECP, FDA, HDM, ICAM, NFR, RC, SCIT, SLIT, SPT, SR
Plan
![]() Disclosure of potential conflict of interest: L. Cox is on the advisory board for Greer, Genentech/Novartis, and Clinical Therapeutics Local Respiratory and is on the speakers’ bureau for GlaxoSmithKline, Pfizer, and AstraZeneca. D. Linnemann has consultant arrangements with MSD, Schering Plough, and Glaxo and is on the speakers’ bureau for MSD, Schering Plough, Almirall, and Boehringer-Ingelheim. D. Weldon is on the speakers’ bureau for GlaxoSmithKline and Sanofi-Aventis and is honoraria for AstraZeneca. The rest of the authors have declared that they have no conflict of interest. Reprint requests: Lauri Sweetman, American Academy of Allergy, Asthma and Immunology, 611 E Wells St, Milwaukee, WI 53203. E-mail: lsweetman@aaaai.org. |
Vol 117 - N° 5
P. 1021-1035 - mai 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?